HOME >> MEDICINE >> NEWS
New drug to treat enlarged prostate developed at UCL

Millions of men stand to benefit from a discovery by UCL scientists that could provide a breakthrough in the treatment of enlargement of the prostate (BPH). The UCL team has developed a new drug, Rho-kinase inhibitor that, in preliminary tests, has been found to treat the condition by both relaxing the prostate and stopping the growth of cells within it. Their findings are set out in the current issue of the Journal of Urology.

BPH affects approximately 85% of men over the age of 50 and causes frequent urination and irritation due to the obstruction of urine flow. The drugs currently available for treatment of BPH aim to either relax the prostrate or to reduce its size as two separate actions, and also have undesired hormonal effects. These effects, along with the need to take two separate treatments, often lead to problems of patient compliance. The discovery by the UCL scientists is novel in that this new drug can both relax the prostate and stop it from growing, with virtually no hormonal side effects.

Dr Selim Cellek, who led the investigation as a collaborative work between UCL's Wolfson Institute for Biomedical Research and its Institute of Urology and Nephrology, said: "We are very excited by this discovery, as it is a medical breakthrough which represents a major advance in treating a condition that affects such a large proportion of the population. We are still at the development stages and more research will be required before the new treatment becomes available. The next step will be to develop links with investors interested in developing this drug for the treatment of BPH.

"Research has shown that this type of compound can also be used to treat erectile dysfunction (impotence). The future for this line of research is therefore promising since men with an enlarged prostate often suffer from impotence. "

Malcolm Grant, UCL Provost, said: "The conversion of scientific results into new medicines is one of the main aims of th
'"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-207-679-9728
University College London
27-Nov-2003


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug treat enlarged prostate developed UCL

(Date:9/3/2015)... ... 2015 , ... TransPack Toon gives users a set of 90 cartoon transitions ... transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and ... Toon features 90 cartoon transitions from 30 unique styles. Editors can choose between ...
(Date:9/3/2015)... , ... September 03, 2015 , ... William Mattar Law ... Mattar, Esq. believes this does not stop at any certain demographic or segment of ... newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will ...
(Date:9/3/2015)... Manchester, NH (PRWEB) , ... September 03, 2015 ... ... a new agreement with Amerinet Inc., a leading national healthcare solutions organization, to ... to Epic EMR. , Through this agreement, Amerinet members will receive negotiated pricing ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo School of Graduate Medical ... Center for Hospice Care (CHC) for physician Hospice and Palliative Medicine Fellowship training ... of fulfilling their requirements for obtaining national Board Certification in Hospice and Palliative ...
(Date:9/3/2015)... ... September 03, 2015 , ... DriButts, a non-profit organization dedicated ... Product Development Group to manufacture a long-lasting reusable diaper for warm weather climates ... to bring 600 DriButts Diapers to rural areas of Haiti during a trip ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3
(Date:9/3/2015)... and ALISO VIEJO, Calif. , ... AGN ), a leading global pharmaceutical company, and ... company focused on developing ocular implants that reduce ... that they have entered into an agreement under ... transaction.  Under the terms of the agreement, Allergan ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... the "Global Medical Devices Packaging Market - By ... Forecasts 2014 - 2020" report to their offering. ... market is driven directly by its end use industry, ... in the packaging of these devices so as to ...
(Date:9/3/2015)... 03, 2015 Research and ... "Investigation Report on China,s Entecavir Market, 2010-2019" ... people infected with hepatitis B virus (HBV) exceeds 100 ... 20-30 million suffering from chronic Hepatitis B. About 0.5 ... and liver cancer caused by chronic Hepatitis B, causing ...
Breaking Medicine Technology:Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 2Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 3Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 4Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 5Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 7Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 8China Entecavir Market Report 2010-2019 2
Cached News: